Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium on May 18, 2021, at 10:30 am ET. CEO Myron Holubiak will discuss corporate strategy and key pipeline assets, including Mino-Lok®, an advanced treatment for catheter-related bloodstream infections, and NC i-MSC, a novel stem cell therapy for Acute Respiratory Distress Syndrome (ARDS), worsening due to COVID-19. Mino-Lok® is in a Phase 3 trial and has received Fast Track designation from the FDA. For registration, visit the event website.
- None.
- None.
CRANFORD, N.J., May 11, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.
Event Details:
Date: May 18, 2021
Time: 10:30am ET
Investors may register for the conference at the event website.
Citius President and Chief Executive Officer Myron Holubiak will focus on the execution of corporate strategy and capital deployment as the Company advances key pipeline assets including Mino-Lok®, a late-stage antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), and NC i-MSC, a novel stem cell therapy for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, and the most common cause of respiratory failure and death in COVID-19 patients. Currently, there is no FDA-approved drug therapy available for ARDS.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Andrew Scott
Vice President, Special Projects
T: 908-967-6677 x105
E: ascott@citiuspharma.com
Ilanit Allen
T: 908-967-6677 x113
E: iallen@citiuspharma.com
View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-fireside-chat-at-the-gabelli-funds-virtual-microcap-symposium-on-tuesday-may-18-301289094.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When is Citius Pharmaceuticals participating in the Gabelli Funds Virtual Microcap Symposium?
What time will Citius Pharmaceuticals' fireside chat take place?
Who is presenting for Citius Pharmaceuticals at the event?
What topics will be discussed during the Citius Pharmaceuticals fireside chat?
What is Mino-Lok® and its significance for Citius Pharmaceuticals?
What is NC i-MSC and its relevance to COVID-19?
Is Mino-Lok® FDA approved?
